Most failed syntheses trace to a small number of causes, and identifying which one applies is faster than changing reagents at random.
Key Takeaways
- Hydrophobic or beta-sheet-prone sequences associate with each other on the support, blocking the N-terminus from reacting.
- Valine, isoleucine, and protected arginine couple slowly because of steric bulk.
- Analyse the crude LC-MS before repeating a synthesis.
On-resin aggregation
Hydrophobic or beta-sheet-prone sequences associate with each other on the support, blocking the N-terminus from reacting. The characteristic signature is a sudden drop in coupling efficiency partway through a previously well-behaved synthesis.
Interventions that work
Lowering resin substitution, raising temperature, switching to a more polar solvent system, and adding chaotropic salts all disrupt interchain association. Pseudoproline dipeptides and backbone-protecting groups interrupt the hydrogen-bonding pattern directly and are often the most effective fix.
For related mechanism work, see native chemical ligation.
Sterically hindered residues
Valine, isoleucine, and protected arginine couple slowly because of steric bulk. Extended coupling times, double coupling, or a more potent activating reagent usually resolve these cases.
Sequence-specific side reactions
Aspartimide formation affects Asp-Gly and Asp-Ser motifs under base treatment, and N-terminal glutamine can cyclise to pyroglutamate. Recognising the motif in advance lets the synthesis be planned around it.
Diagnosing rather than repeating
Analyse the crude LC-MS before repeating a synthesis. The mass differences present identify whether the problem is deletion, incomplete deprotection, adduct formation, or aggregation, and each has a different remedy.
Experimental Conditions and Practical Setup
Diagnosis starts with the crude LC-MS rather than with a repeat synthesis. Mass differences reveal whether the problem is a deletion sequence, an incomplete deprotection, an adduct, or aggregation, and each has a different remedy. Repeating the synthesis unchanged before looking at the data is the most common wasted cycle.
Failure signature to cause mapping
| Observation in crude | Likely cause | Intervention |
|---|---|---|
| Mass lower by one residue | Incomplete coupling | Double coupling, longer time |
| Mass higher by a protecting group | Incomplete deprotection | Extended deprotection |
| Sudden efficiency drop mid-chain | On-resin aggregation | Lower loading, pseudoproline, heat |
| Mass plus 56 or 100 units | Side reaction adduct | Adjust scavenger cocktail |
Practical Notes for the Bench
- Read the crude LC-MS before repeating a failed synthesis.
- Use pseudoproline dipeptides where beta-sheet aggregation is suspected.
- Check for known motifs such as Asp-Gly before synthesis begins.
Frequently Asked Questions
What is the most common cause of failure?
On-resin aggregation of the growing chain, which blocks the N-terminus and shows as a sudden efficiency drop.
What are pseudoproline dipeptides?
Building blocks that temporarily disrupt backbone hydrogen bonding, preventing the interchain association that causes aggregation.
Should I change the coupling reagent first?
Only if activation is the actual problem. Diagnose from the crude mass data before changing chemistry.
Is raising the temperature a safe first fix?
It is a reasonable intervention for aggregation, but it increases racemisation risk at histidine and cysteine. Change one variable at a time so the effect is interpretable.
Related Reading
- native chemical ligation
- peptide coupling reagents
- preparative HPLC peptide purification
- buffer preparation peptides
- peptide drug candidate criteria
References & Further Reading
- Due Larsen B et al. Sequence-assisted peptide synthesis (SAPS). J Pept Res. 1998. PubMed 9924991
- Tamás B et al. Amino acid composition drives aggregation during peptide synthesis. Nat Chem. 2026. PubMed 41862614
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- USP general chapters on pharmaceutical analysis
Content here is written for researchers handling peptide reagents. It does not constitute medical guidance, dosing advice, or an endorsement of any supplier.
Reviewed by Dr. Elena Marchetti, Peptide Chemistry & Analytical Characterization.